Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Interleukin-25 on trial in IPF
September 2019
SHARING OPTIONS:

WASHINGTON—The recent discovery of a new therapeutic target for idiopathic pulmonary fibrosis (IPF) could open up new treatment options for a disease that claims more than 50,000 lives annually in the United States alone. A study led by Dr. Huaping Dai in the Department of Pulmonary and Critical Care Medicine and the Center of Respiratory Medicine at China-Japan Friendship Hospital and the National Clinical Research Center for Respiratory Disease in Beijing found that interleukin-25 levels (protein and mRNA) are elevated in IPF patients and that the inflammatory cytokine contributed to lung fibrosis in an animal model. At present, there is no cure for IPF and no treatments that can resolve the lung scarring that characterizes the disease. According to Dai, “[T]reatment targeting IL-25 may be a novel method for treating IPF patients.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.